2. Academic Validation
  3. Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound

  • Bioanalysis. 2021 Dec;13(23):1761-1777. doi: 10.4155/bio-2021-0194.
Ashok M Ghoghari 1,  Harilal V Patel 1,  Nisarg N Nayak 1,  Tariq H Mansuri 1,  Soma M Pillai 1,  Mukul R Jain 1,  Hardik B Patel 2,  Kevin Kansagra 2,  Ilaria Di Resta 3,  Jörg Möhrle 3,  Deven V Parmar 4
Affiliations

Affiliations

  • 1 Bioanalytical Laboratory, Zydus Research Centre, Ahmedabad, Gujarat, India.
  • 2 Clinical Research, Zydus Research Centre, Ahmedabad, Gujarat, India.
  • 3 Medicines for Malaria Venture, Geneva, Switzerland.
  • 4 Zydus Therapeutics Inc., NJ 08534, USA.
PMID: 34779650 DOI: 10.4155/bio-2021-0194
Abstract

Aim: ZY-19489 is a new antimalarial drug candidate and selective LC-MS/MS method was established for estimation of ZY-19489 and its metabolite in human plasma. Materials & methods: LLE was employed for extraction, mass spectrometric quantification performed using positive ionization mode and DCP-IMP was used as an internal standard. The chromatographic separation was achieved using mobile phase 5 mM ammonium formate in water and 0.1% v/v ammonia solution in methanol:acetonitrile (90:10% v/v) and column Agilent Zorbex Extended C18, 3.5 μm, 100 × 4.6 mm with a 6-min run time. Results: The calibration curve of ZY-19489 was linear over range 1-500 ng/ml and 2-200 ng/ml for metabolite. Assay was reproducible, selective and devoid of matrix effect. Conclusion: The validated assay was implemented for clinical sample analysis derived from healthy human subjects and parasitemia-induced subjects.

Keywords

LC–MS/MS; ZY-19489; ZY-20486; human plasma; method validation.

Figures
Products